Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the completed acquisition of Affinity Biologicals Inc., a primary manufacturer of reagents and kits used in hemostasis and thrombosis research and diagnostics.
“This acquisition marks an important step in the development of our company and execution of our strategic plan,” says Paul Empey, President & CEO of Precision BioLogic. “The two organizations serve a similar market with complementary product lines, which will allow us to better serve existing customers and develop new products for research and diagnostics.”
Affinity President Hugh Hoogendoorn agrees. “It’s a logical fit,” he says. “Affinity and Precision BioLogic share many of the same guiding principles, including a commitment to quality products and service. The resulting synergy will create exciting opportunities for us and our customers.”
The two organizations will continue to focus on their customers and regular operations while developing longer term strategic plans under the Precision BioLogic umbrella.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Date: November 5, 2018
Source: Cision
